Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Johnson & Johnson Jumped Higher Today

By Brian Orelli, PhD - Mar 30, 2020 at 2:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The healthcare conglomerate has made substantial progress developing a vaccine for COVID-19.

What happened

Shares of Johnson & Johnson (JNJ 0.29%) are up 6.4% at 1:50 p.m. EDT after the healthcare conglomerate said it's made considerable progress developing a vaccine for COVID-19, the disease caused by the novel coronavirus.

Earlier this month Johnson & Johnson's chief scientific officer, Dr. Paul Stoffels, said the company had a goal of starting a clinical trial in November, but Johnson & Johnson now thinks it can be in the clinic by September at the latest.

Gloved hands giving an injection into a patient's shoulder

Image source: Getty Images.

So what

"What would usually take five to seven years, we expect to be able to accomplish in five to seven months," Alex Gorsky, chairman and CEO of Johnson & Johnson, said in an interview on NBC News' Today Show.

Johnson & Johnson is ramping up production of the vaccine before the healthcare company even knows whether the vaccine works with a goal of having "several hundred million doses available by the middle of next year" according to Gorsky. Longer term, Gorsky thinks Johnson & Johnson can have a billion doses available by the end of 2021.

The vaccine is being co-funded by the U.S government's Biomedical Advanced Research and Development Authority (BARDA). Johnson & Johnson and BARDA have committed more than $1 billion of investment into research, development, and clinical testing of the vaccine.

Now what

Johnson & Johnson plans to make the vaccine available for emergency use -- presumably for people at high risk of exposure like healthcare workers -- in early 2021. It won't make a profit on the emergency use vaccinations, but should benefit once the vaccine is approved by the Food and Drug Administration.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$170.67 (0.29%) $0.49

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.